Global In-situ Hybridization (ISH) Market 2017-2021
About In-Situ Hybridization (ISH)
ISH is a technique for localizing specific nucleic acid targets within fixed tissues and cells, providing temporal and spatial information about gene expression and genetic loci. While the basic workflow of ISH is similar to that of blot hybridizations, the nucleic acid probe is synthesized, labeled, purified, and annealed with the specific target; the difference is the greater amount of information gained by visualizing the results within the tissue. Technavio’s analysts forecast the global in-situ hybridization (ISH) market to grow at a CAGR of 6.59% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global in-situ hybridization (ISH) market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of reagents and instruments used to conduct ISH.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global In-situ Hybridization (ISH) Market 2017-2021
Technavio recognizes the following companies as the key players in the global in-situ hybridization (ISH) market: Abbott, Agilent Technologies, F. Hoffmann-La Roche, and Thermo Fisher Scientific
Other Prominent Vendors in the market are: Advanced Cell Diagnostics, Biocare Medical, Bio SB, BioDot, BioGenex, Cytocell, Exiqon, Genemed Biotechnologies, LGC Biosearch Technologies, Leica Biosystems, Merck, Mirius Bio, and PerkinElmer.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Increasing M&A activity in molecular diagnostics market. Diagnostic companies are progressively seeking strategic opportunities to enhance their competencies in the molecular diagnostics sector and tap into the market’s growth potential. The global molecular diagnostics market is poised to grow at a high rate and reach over $7 billion by 2022. Industry experts and KOLs believe that PCR, NGS, microarray, and ISH, especially FISH, are the dominant technologies in the space. Particularly for ISH, a major trend of partnerships is being observed as one company focuses on developing the therapy for a drug, while the other company focuses on developing the companion diagnostic test. Both companies benefit immensely from such deals as a synergistic growth opportunity is seen along with portfolio expansion.”
According to the report, one of the major drivers for this market is Growing incidence and prevalence of cancer. Globally, cancer is among the top five causes of death across all age groups. The various types of cancer contribute to significant deaths across all regions in the world. However, the low and middle-income countries are the worst-affected regions. Cancer caused by tobacco is the most common type of cancer in these countries, which is also the most-easily preventable.
Further, the report states that one of the major factors hindering the growth of this market is Emergence of alternative techniques. Although FISH provides considerable cost benefit and superior performance when compared with other molecular IVD tests, full-scale adoption of this technique is lacking in routine IVD use. When applied to complex samples such as mucoid respiratory samples, results are highly irregular and the procedure intrinsically complex. Although some advancements have been made which remove traditional DNA probes with peptide probes, the resulting IVD assays till date have only managed to address niche markets.
Abbott, Agilent Technologies, F. Hoffmann-La Roche, Thermo Fisher Scientific, Advanced Cell Diagnostics, Biocare Medical, Bio SB, BioDot, BioGenex, Cytocell, Exiqon, Genemed Biotechnologies, LGC Biosearch Technologies, Leica Biosystems, Merck, Mirius Bio, and PerkinElmer.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook